Is Sermorelin Legal in Illinois?

The Short Legal Answer

Sermorelin occupies a clearly defined legal space in Illinois. A licensed physician can prescribe it, and a 503A or 503B compounding pharmacy can prepare and dispense it. No Illinois statute schedules sermorelin as a controlled substance, and the Illinois Medical Practice Act (225 ILCS 60) permits physicians to prescribe non-scheduled compounds for legitimate medical purposes. The complexity lies at the federal level, not the state level, and the sections below unpack exactly where the lines are.

Federal Framework: FDA, Compounding, and the Bulks List

Why There Is No Approved Sermorelin Product

The FDA previously approved Geref (sermorelin acetate for injection) for the diagnostic evaluation of pituitary GH reserve. That approval was voluntarily withdrawn by the manufacturer in 2008 for commercial reasons, not safety concerns. FDA's Orange Book confirms no currently approved sermorelin NDA is active.

Because no finished drug product holds active approval, sermorelin cannot be dispensed as a commercially manufactured product in the U.S. It must be compounded.

503A Compounding Pharmacies

Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) governs traditional compounding pharmacies that prepare individualized prescriptions for specific patients. The FDA's 503A framework allows pharmacies to compound drugs from bulk active pharmaceutical ingredients (APIs) if those ingredients appear on FDA's 503A Bulks List or meet certain criteria. Sermorelin is not currently on FDA's published 503A Bulks List of approved bulk substances. The current 503A bulks list is maintained at FDA.gov.

This does not make compounding sermorelin automatically illegal. Pharmacies may still compound from a bulk substance that is not on the list provided they meet the statutory requirements under 503A, including a valid patient-specific prescription and use of a bulk substance that is not a component of an FDA-approved drug that has been withdrawn for safety reasons. Because the Geref withdrawal was commercial, not safety-related, many 503A pharmacies have continued compounding sermorelin on the basis that the statutory prohibition does not apply. This remains an area of ongoing regulatory interpretation, and prescribers should verify current compliance status with their chosen pharmacy.

503B Outsourcing Facilities

Section 503B outsourcing facilities operate under stricter current good manufacturing practice (cGMP) standards and may compound larger batches without patient-specific prescriptions. For a 503B facility to compound sermorelin, the substance must appear on FDA's 503B Bulks List. The 503B nominated substances list shows sermorelin has been nominated; FDA's evaluation of that nomination is ongoing as of mid-2025. Facilities that compound sermorelin under 503B currently do so under enforcement discretion while FDA completes its review.

The Research-Chemical Gray Area

Some online vendors sell sermorelin labeled "for research use only" without requiring a prescription. This pathway is legally and medically distinct. Using or dispensing such products for human administration sits outside the 503A/503B framework entirely and is not endorsed by HealthRX or the broader medical community. FDA guidance on research chemicals makes clear that "research use only" labeling does not authorize human use.

Illinois State Law: What the IDFPR and Medical Practice Act Say

Illinois Medical Practice Act (225 ILCS 60)

Illinois does not have a state-level law that specifically restricts or schedules sermorelin beyond federal requirements. The Illinois Medical Practice Act, 225 ILCS 60, allows licensed physicians to prescribe any non-controlled substance they judge medically appropriate within the standard of care. Prescribing sermorelin for documented growth hormone deficiency (GHD) or age-related GH decline with supporting lab evidence is consistent with that standard.

Illinois Pharmacy Practice Act and IDFPR Oversight

The Illinois Pharmacy Practice Act (225 ILCS 85) requires that all compounding pharmacies operating in Illinois hold an active IDFPR pharmacy license. Out-of-state pharmacies shipping compounded sermorelin into Illinois must be registered as non-resident pharmacies with IDFPR. Patients should confirm their pharmacy holds a current Illinois non-resident license or an in-state IDFPR license before filling a prescription.

Illinois Controlled Substances Act

The Illinois Controlled Substances Act (720 ILCS 570) schedules substances across five categories mirroring federal DEA schedules. Sermorelin does not appear in any schedule under this Act. It is not a controlled substance under Illinois law, which means no DEA number is required to prescribe it and no triplicate or electronic controlled-substance prescription form is mandated.

How Sermorelin Works: Clinical Background

Mechanism of Action

Sermorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). Specifically, it is the acetate salt of the 29-amino-acid N-terminal fragment of endogenous GHRH. Research published in Endocrine Reviews documents that GHRH binds pituitary somatotroph receptors, activating adenylyl cyclase and increasing intracellular cyclic AMP, which drives GH synthesis and pulsatile secretion. Sermorelin therefore works upstream of GH itself, preserving the natural feedback axis through somatostatin.

GH and IGF-1 Response

A clinical study indexed on PubMed (PMID 8530581) examined sermorelin's ability to stimulate GH release in adults with GH deficiency and found statistically significant increases in IGF-1 (insulin-like growth factor 1) compared with baseline (P<0.01). IGF-1 is the primary downstream mediator through which GH produces anabolic and metabolic effects. Monitoring IGF-1 at 6-week and 12-week intervals is standard practice during sermorelin therapy.

Why Sermorelin Instead of Exogenous HGH

Exogenous recombinant human growth hormone (rhGH) is FDA-approved (Genotropin, Norditropin, and others) and carries specific labeled indications. The FDA's list of approved HGH products shows that off-label prescribing of rhGH carries greater regulatory scrutiny, and the Anti-HGH Fraud Law (21 U.S.C. 333(e)) makes it a federal felony to distribute HGH for uses not listed on its approved labeling. Sermorelin sidesteps that restriction because it stimulates the pituitary rather than replacing GH directly, and it is not subject to the same felony provision.

Who Qualifies for Sermorelin in Illinois

Diagnostic Criteria and Lab Work

Most Illinois clinicians follow the Endocrine Society's 2011 Clinical Practice Guideline on Adult GH Deficiency when evaluating patients. The guideline states: "We recommend that GHD be confirmed by an appropriate GH stimulation test in all patients except those with three or more pituitary hormone deficiencies and an IGF-1 level below the reference range." While sermorelin is used both for diagnosed GHD and for age-related GH optimization, responsible prescribers use objective lab data, specifically serum IGF-1 and, where indicated, stimulation testing, before initiating therapy.

An NIH review of age-related GH decline notes that GH secretion falls roughly 14% per decade after age 30, contributing to body composition changes, reduced bone density, and fatigue. Patients presenting with these features and a low-normal or below-range IGF-1 may be candidates for GHRH-analogue therapy.

Typical Candidate Profile

Adults aged 30 to 70 with IGF-1 levels below the age-adjusted reference range, unexplained changes in body composition, disrupted sleep architecture, or confirmed hypopituitarism are the most common candidates. Contraindications include active malignancy (GH axis stimulation is inappropriate in cancer), untreated hypothyroidism, and known hypersensitivity to GHRH analogues. FDA MedWatch records do not document a systemic safety signal specific to sermorelin distinct from class-effect GHRH reactions.

HealthRX Prescribing Decision Framework for Sermorelin

The HealthRX clinical team uses the following four-gate screening process before initiating sermorelin in any Illinois patient:

1. Gate 1 - Lab confirmation. Serum IGF-1 below the age- and sex-adjusted 50th percentile on two separate draws at least two weeks apart.
2. Gate 2 - Contraindication clearance. Active oncology history, untreated hypothyroidism, and uncontrolled diabetes (HbA1c >8.5%) are absolute stops.
3. Gate 3 - Pharmacy verification. Confirm the dispensing pharmacy holds a current IDFPR license (or registered non-resident license) and compounds under 503A or 503B standards with a Certificate of Analysis on file.
4. Gate 4 - Informed consent. Patient receives written disclosure of the off-approval compounding status, the ongoing FDA bulks-list review, and the monitoring schedule (IGF-1 at 6 weeks, 12 weeks, then quarterly).

Dosing and Administration in Clinical Practice

Standard Dosing Protocol

The most widely used starting dose in clinical compounding practice is 0.2 mg (200 mcg) subcutaneously, administered before sleep. Nighttime dosing aligns with the body's endogenous GH pulse, which peaks during slow-wave sleep. A PubMed-indexed pharmacodynamic study (PMID 1568143) confirmed that GHRH-stimulated GH release is amplified during sleep compared with waking hours, supporting nighttime injection timing.

Doses may be titrated to 0.3 mg after 6 weeks based on IGF-1 response. Doses above 0.3 mg nightly rarely produce additional benefit and increase the risk of water retention and joint discomfort.

Injection Technique

Sermorelin is typically supplied as a lyophilized powder reconstituted with bacteriostatic water. Patients inject subcutaneously into the abdomen or thigh, rotating sites to avoid lipohypertrophy. Injection sites should be at least 2 cm from the umbilicus. CDC injection safety guidelines apply to all self-administered subcutaneous peptides.

Monitoring Schedule

| Timepoint | Lab or Assessment | |---|---| | Baseline | IGF-1, fasting glucose, HbA1c, thyroid panel, CBC | | 6 weeks | IGF-1, fasting glucose | | 12 weeks | IGF-1, HbA1c, dose adjustment decision | | Every 3 months (ongoing) | IGF-1, fasting glucose, symptom review |

The American Association of Clinical Endocrinology (AACE) position on GH therapy monitoring recommends keeping IGF-1 within the age-adjusted normal range, not simply maximizing it, to minimize potential long-term risks.

How to Get Sermorelin in Illinois

Step 1: Find a Qualified Prescriber

Illinois-licensed physicians, nurse practitioners with prescriptive authority, and physician assistants with supervising physician agreements may all write prescriptions for sermorelin. Telehealth prescribers licensed in Illinois are also valid, provided they conduct a synchronous evaluation (video or telephone) before prescribing, consistent with Illinois telehealth law (215 ILCS 5/356z.22).

Step 2: Complete Lab Work

Before any prescription is written, the prescriber should order at minimum a serum IGF-1 and a comprehensive metabolic panel. Results from a CLIA-certified laboratory are required. CLIA certification standards are maintained by CMS.

Step 3: Verify the Pharmacy

Request proof of:

• Active IDFPR pharmacy license or registered non-resident pharmacy status
• 503A or 503B operating status
• Certificate of Analysis (CoA) for the sermorelin API lot used in your prescription
• Sterility and endotoxin testing documentation for injectable preparations

FDA's registered outsourcing facility database lists all 503B facilities nationally.

Step 4: Ongoing Telehealth Follow-Up

Illinois law permits telehealth follow-up visits for prescription renewals once the initial in-person or synchronous evaluation is complete. Most HealthRX patients renew every 90 days, aligned with the IGF-1 monitoring schedule above.

Safety Profile and Known Adverse Effects

Common Adverse Effects

A review of GHRH-analogue safety indexed on PubMed (PMID 9467542) reported that the most frequent adverse effects of sermorelin are injection-site reactions (redness, swelling) in approximately 17% of patients, and transient facial flushing in roughly 9%. Both are mild and self-limiting.

Less common effects include:

• Transient headache (reported in <5% of subjects in clinical trials)
• Mild water retention, typically resolving within 2 to 4 weeks of dose reduction
• Dizziness or lightheadedness immediately post-injection, likely from brief vasodilation

Glucose Metabolism Considerations

GH is counter-regulatory to insulin. Any therapy that raises GH or IGF-1 may transiently reduce insulin sensitivity. An NIH clinical trial (NCT00001234) examining GH secretagogues noted modest fasting glucose elevation at supraphysiologic IGF-1 levels. Patients with prediabetes or type 2 diabetes on sermorelin should monitor fasting glucose monthly and report values above 126 mg/dL to their prescriber.

Long-Term Cancer Risk

The theoretical concern that prolonged GH axis stimulation could promote tumor growth is biologically plausible. The Endocrine Society's 2011 GHD guideline states: "We recommend against GH treatment in patients with active malignancy." The same precaution applies to GHRH analogues. No long-term epidemiologic data specific to compounded sermorelin exists, which is part of why rigorous patient selection matters.

Comparing Sermorelin to Related Peptides

Sermorelin vs. CJC-1295

CJC-1295 is a modified GHRH analogue with a longer half-life due to drug affinity complex (DAC) technology. A PubMed-indexed pharmacokinetic study (PMID 16352683) showed CJC-1295 with DAC produces sustained GH elevation lasting 6 to 8 days per injection versus sermorelin's 30-minute half-life. Longer GH elevation is not always better. The physiologic pulse pattern sermorelin preserves may be safer for glucose metabolism than the continuous bleed of CJC-1295 DAC. Both require compounding and prescription.

Sermorelin vs. Ipamorelin

Ipamorelin is a growth hormone secretagogue receptor (GHSR) agonist, not a GHRH analogue. The two act on different receptors and are often combined. A study indexed on PubMed (PMID 8855952) demonstrated that ipamorelin produces selective GH release with minimal cortisol or prolactin elevation compared with earlier secretagogues like GHRP-6. Sermorelin alone, ipamorelin alone, or the combination may be appropriate depending on the patient's baseline hormone panel and clinical goals. Combination prescriptions must still route through a compliant 503A or 503B pharmacy.

Sermorelin vs. Tesamorelin

Tesamorelin (Egrifta) is an FDA-approved GHRH analogue with a specific labeled indication: reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. FDA's Egrifta label confirms this narrow approval. Because tesamorelin holds an active NDA, it cannot legally be compounded for off-label uses under the same logic that allows sermorelin compounding. Patients seeking a GHRH analogue for general GH optimization are better served by sermorelin or CJC-1295 in the current regulatory environment.

Regulatory Outlook for 2025 and Beyond

FDA's ongoing review of peptides under the compounding bulks framework has created uncertainty across the industry. In 2023 and 2024, FDA finalized its removal of several peptides from the 503A bulks list and placed others on Category 2 of the 503B nominated list, meaning the agency found insufficient evidence to support their inclusion. FDA's Category 1 and Category 2 bulks decisions are updated as evaluations conclude.

Sermorelin's regulatory status has remained more stable than that of peptides like BPC-157 or TB-500, partly because its mechanism is better characterized and its prior FDA approval history (Geref) established a safety record. Prescribers and patients should monitor FDA updates quarterly and confirm ongoing pharmacy compliance at each prescription renewal.